NEW YORK (GenomeWeb) – Qiagen expects to be a dominant player in the nascent liquid biopsy space, with a growing number of the firm's widely-used products finding prominence under that tent. In a recent interview with GenomeWeb, the company offered insights into its liquid biopsy business, and also clarified its business relationship with Exosome Diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.